-+ 0.00%
-+ 0.00%
-+ 0.00%

Shanghai Henlius says China NMPA clears Phase 1 trial of HLX37 with chemo or HLX43 in solid tumors

PUBT·07/10/2026 08:31:00
Listen to the news
Shanghai Henlius says China NMPA clears Phase 1 trial of HLX37 with chemo or HLX43 in solid tumors
  • China’s NMPA cleared an IND for a Phase 1 trial of Henlius’ HLX37 in advanced or metastatic solid tumors.
  • Study tests HLX37 with chemotherapy or with HLX43, a PD-L1 antibody-drug conjugate.
  • Henlius plans to start the China mainland trial once conditions are met.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Shanghai Henlius Biotech Inc. published the original content used to generate this news brief via IIS, the regulatory disclosure system operated by the Hong Kong Stock Exchange (HKex) (Ref. ID: HKEX-EPS-20260710-12240689), on July 10, 2026, and is solely responsible for the information contained therein.